Everolimus and mTOR inhibition in pancreatic neuroendocrine tumors

Pancreatic neuroendocrine tumors are rare and the majority of patients present in the advanced stage. Over the past few decades, treatment for patients with metastatic well- or moderately differentiated pancreatic neuroendocrine tumors have not significantly impeded tumor progression nor improved su...

Descripción completa

Detalles Bibliográficos
Autor principal: Yim, Kein-Leong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2012
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3421470/
https://www.ncbi.nlm.nih.gov/pubmed/22904642
http://dx.doi.org/10.2147/CMAR.S25979

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3421470/
https://www.ncbi.nlm.nih.gov/pubmed/22904642
http://dx.doi.org/10.2147/CMAR.S25979

Ejemplares similares